Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study to Assess the Safety and Efficacy of Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

Next Previous
Trial Profile

A Phase II Study to Assess the Safety and Efficacy of Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Tocilizumab (Primary)
  • Indications Bladder cancer; Carcinoma; Malignant melanoma; Non-small cell lung cancer; Pelvic cancer; Renal cancer; Skin cancer; Transitional cell carcinoma; Ureteral neoplasms; Urethral cancer; Urogenital cancer
  • Focus Adverse reactions

Most Recent Events

  • 22 Dec 2025 Planned End Date changed from 31 Dec 2025 to 31 Dec 2027.
  • 22 Dec 2025 Planned primary completion date changed from 31 Dec 2025 to 31 Dec 2027.
  • 19 Sep 2024 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top